Madhuri Badrinath, MD
Gastroenterology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 20
- 4 carriers
- Offices
- 2
Offices
2 locations · Regents of the University of California - UCSF · County of Santa Clara
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
20 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Badrinath’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
20 of 20 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
State licence records
1 licence
- Texas U5071Physician License · since 2023 · expires 2025-08-31Canc Non-RenewalNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$37,293
Medicare paid this office $37,293 for 279 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 30 | $6,038 | $195 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $5,799 | $129 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 45 | $3,077 | $68 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 13 | $2,636 | $203 |
| Short return visit (20+ min) | 41 | $2,373 | $47 |
See all 11 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 30 | $6,038 | $195 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $5,799 | $129 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 45 | $3,077 | $68 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 13 | $2,636 | $203 |
| Short return visit (20+ min) | 41 | $2,373 | $47 |
| Biopsy of large bowel using a flexible endoscope | 25 | $2,023 | $81 |
| New patient visit (30+ min) | 33 | $1,555 | $47 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,255 | $78 |
| Return visit (30+ min) | 16 | $958 | $60 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 27 | $111 | $4 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 11 | $49 | $4 |
Procedures Medicare counted
| Colonoscopy | 12 | More than 42% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 15 | More than 47% of doctors who do this |
Who their Medicare patients are
279 Original Medicare patients in 2024. Average age 72 · Under 65 12% · 85 and older 7% · Women 59% · Also on Medicaid 10% · Health risk score 1.84. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 41% · Depression 34% · Chronic kidney disease 30% · Coronary heart disease 27% · Heart failure 24% · Atrial fibrillation 23% · COPD 21% · Cancer 17% · Stroke 16% · Dementia 9%.
The office billed $291,419, Medicare allowed $46,911 and paid $37,293; for 431 services of 32 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 279 | 431 | 72 | 1.84 | $291,419 | $37,293 |
| 2023 | 53 | 77 | 72 | 1.45 | $53,148 | $6,575 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| New patient visit (30+ min) | 12 | $757 | $63 |
Drugs they prescribed that Part D paid
$48,803
Pharmacies billed $48,803 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 213) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
175 generic and 38 brand-name prescriptions · $48,803 in drug cost · 16 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 13 | $15,690 | $1,207 |
| Mesalamine | 14 | $2,048 | $146 |
| Pantoprazole | 40 | $609 | $15 |
| Famotidine | 26 | $345 | $13 |
| Ondansetron | 14 | $306 | $22 |
See all 7 drugs
| Linzess | 13 | $15,690 | $1,207 |
| Mesalamine | 14 | $2,048 | $146 |
| Pantoprazole | 40 | $609 | $15 |
| Famotidine | 26 | $345 | $13 |
| Ondansetron | 14 | $306 | $22 |
| Omeprazole | 18 | $283 | $16 |
| Dicyclomine | 17 | $251 | $15 |
Year by year
| 2024 | 213 | 93 | 0% (0) | 18% | $48,803 |
| 2023 | 173 | 57 | 0% (0) | 29% | $414,800 |
| 2022 | 174 | 75 | 0% (0) | 23% | $203,079 |
| 2021 | 111 | 53 | 0% (0) | None | $24,948 |
| 2020 | 135 | 23 | 0% (0) | 11% | $6,042 |
| 2019 | 245 | 32 | None | 11% | $4,493 |
| 2018 | 228 | 23 | None | None | $5,998 |
| 2017 | 36 | 14 | 0% (0) | None | $632 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Humira(Cf) | 19 | $216,307 | $11,385 |
| Humira(Cf) | 11 | $83,039 | $7,549 |
| Ursodiol | 11 | $1,266 | $115 |
| Esomeprazole Magnesium | 11 | $762 | $69 |
| Pantoprazole | 40 | $531 | $13 |
2022: 3 drugs
| Humira(Cf) | 13 | $90,389 | $6,953 |
| Ursodiol | 22 | $5,009 | $228 |
| Pantoprazole | 65 | $805 | $12 |
2021: 3 drugs
| Esomeprazole Magnesium | 12 | $1,572 | $131 |
| Pantoprazole | 41 | $590 | $14 |
| Omeprazole | 12 | $170 | $14 |
2020: 2 drugs
| Amlodipine Besylate | 11 | $37 | $3 |
| Hydrochlorothiazide | 11 | $31 | $3 |
2019: 6 drugs
| Levothyroxine | 14 | $199 | $14 |
| Clopidogrel | 11 | $141 | $13 |
| Spironolactone | 11 | $102 | $9 |
| Lisinopril | 16 | $76 | $5 |
| Amlodipine Besylate | 19 | $72 | $4 |
| Atenolol | 11 | $32 | $3 |
2018: 5 drugs
| Nifedipine Er | 11 | $439 | $40 |
| Levothyroxine | 15 | $203 | $14 |
| Atorvastatin | 14 | $111 | $8 |
| Lisinopril | 23 | $109 | $5 |
| Amlodipine Besylate | 24 | $92 | $4 |
Money from drug and device companies
$264 in 2025
| 2025 | 8 | 9 | None | $264 |
| 2024 | 1 | 1 | None | $105 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Madrigal Pharmaceuticals | Rezdiffra | $74 | 2 payments
|
| QOL Medical | Sucraid | $41 | 1 payment
|
| Janssen Biotech | Tremfya | $31 | 1 payment
|
| Abbvie | Rinvoq | $31 | 1 payment
|
| Novo Nordisk | Wegovy | $27 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $27 | 1 payment
|
See all 9 published payments
| Abbvie | Meals · 2025-12-03 | Rinvoq | $31 |
| Madrigal Pharmaceuticals | Meals · 2025-11-26 | Rezdiffra | $35 |
| Madrigal Pharmaceuticals | Meals · 2025-11-20 | Rezdiffra | $39 |
| Novo Nordisk | Meals · 2025-11-12 | Wegovy | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-15 | Entyvio | $27 |
| QOL Medical | Meals · 2025-10-08 | Sucraid | $41 |
| Conmed | Meals · 2025-10-04 | Conmed Biliary | $14 |
| Erbe USA | Meals · 2025-10-04 | Vio3, Apc3, Hapc | $20 |
| Janssen Biotech | Meals · 2025-09-10 | Tremfya | $31 |
See earlier years (2024)
2024: $105
| Takeda Pharmaceuticals U.S.A. | Entyvio | $105 | 1 payment
|
Professional record
- NPI
- 1972030146
- Licence
- TX U5071Texas U5071: Canc Non-Renewal
- Group
- Regents of the University of California - UCSF · County of Santa Clara
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 2495 Hospital Dr Ste 600, Mountain View, CA, 94040
- NPI first listed
- 2017-05-18
- NPI last updated
- 2025-09-16
- NPI record certified
- 2025-09-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1320 Mercy Dr Nw, Canton, OH, 44708 · 2495 Hospital Dr Ste 600, Mountain View, CA, 94040 · 2401 S 31st St, Temple, TX, 76508
This office lists an electronic records connection.